BBNX
Beta Bionics, Inc.
NASDAQ · USHealthcareMedical - Equipment & Services
$17.82+3.07%
Price as of Jul 20, 2026
BBNX financials
Beta Bionics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $100.3M | $65.1M | $12.0M | $179.0K |
| Cost of revenue | $44.7M | $29.2M | $5.7M | $0.00 |
| Gross profit | $55.5M | $35.9M | $6.3M | $179.0K |
| Operating expenses | $127.2M | $81.1M | $42.2M | $66.0M |
| Operating income | -$71.7M | -$45.3M | -$35.9M | -$65.8M |
| Net income | -$73.2M | -$54.8M | -$44.1M | -$64.8M |
| EBITDA | -$70.3M | -$53.6M | -$42.9M | -$63.4M |
| Basic EPS | $-1.81 | $-8.60 | $-8.31 | $-12.96 |
| Diluted EPS | $-1.81 | $-8.60 | $-8.31 | $-12.96 |
| Balance sheet | ||||
| Cash & equivalents | $31.6M | $30.4M | $26.6M | $27.7M |
| Total assets | $328.7M | $149.6M | $110.0M | $35.5M |
| Total liabilities | $41.1M | $73.6M | $51.4M | $22.5M |
| Stockholders’ equity | $287.6M | $76.0M | $58.6M | $13.0M |
| Total debt | $7.3M | $7.3M | $4.2M | $4.1M |
| Net debt | -$24.3M | -$23.2M | -$22.3M | -$23.5M |
| Cash flow | ||||
| Operating cash flow | -$50.9M | -$48.3M | -$32.4M | -$60.2M |
| Capital expenditure | -$5.3M | -$3.4M | -$402.0K | -$772.0K |
| Free cash flow | -$56.2M | -$51.7M | -$32.8M | -$61.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |